TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3028458
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ramipril
Study: 29708589
Drug: Phenylephrine (α1-agonist)
Normalized name: phenylephrine 1.5 MG
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine (α1-agonist) during exercise trials
Study: 29708589
Drug: Dexmedetomidine (α2-agonist)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (α2-agonist) during exercise trials
Study: 29708589
Drug: Resting and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resting and high flow trials with α1 and α2 agonists
Study: 25703911
Drug: Intrarectal prilocaine‐lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal prilocaine‐lidocaine cream application
Study: 25703911
Drug: INB +
Normalized name: Indinavir sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: INB + intrarectal prilocaine‐lidocaine cream application (combined group)
Study: 20606084
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg/d orally for 7 consecutive days (IM-positive group)
Study: 18379217
Drug: Isometric training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric training (IMT) group: 20 exercises of 5-s isometric contraction of knee extensor, flexor, and ankle plantar flexor muscles, twice a day for 2 weeks
Study: 10072029
Drug: nalbuphine 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.08 mg/kg
Study: 10072029
Drug: meperidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 0.4 mg/kg
Study: 2174653
Drug: pH-adjusted lignocaine
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-adjusted lignocaine solutions (1% lignocaine + 1 ml 8.4% sodium bicarbonate)
Study: 6995193
Drug: Carnidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnidazole (2 g single dose)
Study: 29450747
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium breve fermented milk (BFM) - 10 billion bacteria and Lactobacillus acidophilus - 1 billion bacteria, administered one pack per day for 48 weeks
Study: 29450747
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered one pack per day for 48 weeks
Study: 25041994
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 2
Study: 25041994
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 1
Study: 25041994
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 3
Study: 20633465
Drug: Ephedra sinica
Normalized name: EPHEDRA SINICA STEM
DrugBank: Ephedra sinica stem (DB14747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedra sinica (pseudo-ephedrine 31.52 mg)
Study: 20633465
Drug: Evodia rutaecarpa
Normalized name: evodia rutaecarpa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evodia rutaecarpa (evodiamine 6.75 mg, rutaecarpine 0.66 mg)
Study: 10574639
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant positivity
Study: 1953322
Drug: Ga‐As +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga‐As + He‐Ne laser treatment
Study: 6958478
Drug: Beclomethasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 100 micrograms four times daily
Study: 31861349
Drug: High-catechin group
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-catechin group (three daily doses of 57 mg catechins and 100 mg xanthan gum)
Study: 31861349
Drug: Low-catechin group
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-catechin group (one daily dose of 57 mg catechins and 100 mg xanthan gum)
Study: 31861349
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (0 mg catechins and 100 mg xanthan gum)
Study: 29903459
Drug: Single-injection adductor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection adductor canal block (SACB) with 20 mL of 0.25% bupivacaine, 1.67 mcg/mL of clonidine, 2 mg of dexamethasone, 150 mcg of buprenorphine, and 2.5 mcg/mL of epinephrine
Study: 29903459
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal blockade (CACB) with 20 mL of 0.25% bupivacaine and 2.5 mcg/mL of epinephrine followed by an 8 mL/h infusion of 0.125% bupivacaine
Study: 27124028
Drug: Intravenous anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthetics alone (control group)
Study: 18831897
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg once daily)
Study: 10085835
Drug: Simultaneous injection
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous injection
Study: 10085835
Drug: Sequential injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential injection
Study: 2261966
Drug: 15 mg.day‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg.day‐1 oral prednisone (PRD)
Study: 7376025
Drug: Peroesophageal injection
Normalized name: INVESTIGATIONAL DRUGS FOR GASTROESOPHAGEAL REFLUX DISEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroesophageal injection sclerotherapy using a modified, rigid Negus oesophagoscope under general anaesthesia
Study: 7376025
Drug: Intravenous pitressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pitressin
Study: 29889868
Drug: High salience
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salience (pudding) ergogenic placebo supplement
Study: 29889868
Drug: Low salience
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salience (capsules) ergogenic placebo supplement
Study: 27151015
Drug: VAD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD chemotherapy
Study: 22088938
Drug: BCT (tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCT (tobacco dependence treatment before CT scan)
Study: 22088938
Drug: ACT (CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT (CT scan before tobacco dependence treatment)
Study: 19773226
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow cells (BMCs)
Study: 25837499
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg daily
Study: 17635377
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg daily
Study: 10866879
Drug: Ketorolac (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (0.5 mg/kg dose-1) IV after surgery and every 6 h for 48 h
Study: 8149689
Drug: Candoxatril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (200 mg) given twice daily for 10 days
Study: 8149689
Drug: Candoxatril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (200 mg)
Study: 23727759
Drug: Whortleberry fruit
Normalized name: Myrtle whortleberry fruit
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months)
Study: 21502969
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dutasteride 0.5 mg plus tamsulosin 0.4 mg)
Study: 19149835
Drug: l-cystine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-cystine and l-theanine
Study: 16875911
Drug: Pexelizumab bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab bolus plus infusion (n = 2476)
Study: 16875911
Drug: Pexelizumab bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab bolus plus infusion or bolus only (n = 3429)
Study: 3756064
Drug: Aminophylline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 0.2 mg kg‐1 min‐1
Study: 31473512
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg choline/day for 12 weeks
Study: 31473512
Drug: 930 mg
Normalized name: PETROLATUM 930 mg in 1 g TOPICAL OINTMENT [Vitamins A and D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 930 mg choline/day for 12 weeks
Study: 21918168
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL 1% lidocaine)
Study: 21918168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL saline)
Study: 17014595
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg twice daily (BID)
Study: 10736328
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (0.8 g/d)
Study: 10736328
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (1.6 g/d)
Study: 10736328
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (2.4 g/d)
Study: 3073765
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg aspirin per day
Study: 3073765
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg aspirin per day
Study: 11440090
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (BSS), 100 mg/kg/d for 5 days
Study: 7587909
Drug: Orthotic device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthotic device treatment
Study: 2312473
Drug: Caffeine (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (650 mg)
Study: 31243478
Drug: Imrecoxib 100
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imrecoxib 100 mg
Study: 23391776
Drug: Intravenous antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antihypertensive treatment targeting systolic BP <150 mm Hg
Study: 23391776
Drug: Intravenous antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antihypertensive treatment targeting systolic BP <180 mm Hg
Study: 16500015
Drug: ACLS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACLS intervention with early administration of sodium bicarbonate
Study: 8840939
Drug: Bicarbonate administration
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate administration
Study: 9202101
Drug: Caffeine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (240 mg)
Study: 9202101
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee with supplemental caffeine (2 mg/kg body wt)
Study: 3285017
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg daily via gastrointestinal tract for 21 days or until discharge)
Study: 25614603
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinse (CAF) 0.3 g/25 ml
Study: 25614603
Drug: Maltodextrin mouth
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin mouth rinse (MALT) 1.6 g/25 ml
Study: 22633472
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin (sim80)
Study: 22633472
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin and 10 mg ezetimibe (sim10eze10)
Study: 17406757
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment with omeprazole, clarithromycin, and amoxicillin for 7 days
Study: 8971904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 newborns who did not receive antibiotics)
Study: 29336914
Drug: Prasugrel 60mg
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 60mg loading dose (G3)
Study: 29336914
Drug: Prasugrel 30mg
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 30mg loading dose (G2)
Study: 29336914
Drug: Prasugrel 10mg
Normalized name: Prasugrel 10mg Oral tablet
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 10mg loading dose (G1)
Study: 19246029
Drug: Dialectical behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behaviour therapy skills training (DBT‐ST)
Study: 19246029
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group therapy (SGT)
Study: 17259081
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg suprofen
Study: 17259081
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg suprofen
Study: 15088181
Drug: 200 mg/ml
Normalized name: urea 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/ml iodine concentration
Study: 15088181
Drug: 250 mg/ml
Normalized name: urea 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/ml iodine concentration
Study: 15088181
Drug: 300 mg/ml
Normalized name: urea 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/ml iodine concentration
Study: 15088181
Drug: 350 mg/ml
Normalized name: urea 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg/ml iodine concentration
Study: 11257152
Drug: Hyaluronan (Hyalgan)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (Hyalgan) - 2 ml of 500-730 000 MW hyaluronan, 10 mg/ml in saline, one injection per week for 5 weeks
Study: 11257152
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (Depomedrol) - 1 ml of methylprednisolone acetate, 40 mg/ml, one injection per week for 3 weeks
Study: 11257152
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Hyalgan and Depomedrol)
Study: 9732167
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg
Study: 3391872
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 400 mg tid for 7-14 days
Study: 3391872
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base enterocoated pellets in capsules (EB enterocapsules) 500 mg tid for 7-14 days
Study: 3391872
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base enterocoated tablets (EB enterotablets) 500 mg tid for 7-14 days
Study: 3391872
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base enterocoated pellets in capsules (EB enterocapsules)
Study: 3391872
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base enterocoated tablets (EB enterotablets)
Study: 27049100
Drug: Intranasal T-LysYal
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal T-LysYal
Study: 24916336
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with adriamycin plus ifosfamide
Study: 24916336
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with gemcitabine and docetaxel
Study: 21035211
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration
Study: 21035211
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration
Study: 19830486
Drug: Iodixanol (Visipaque,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (Visipaque, GE Healthcare, United Kingdom) administered during endovascular procedure, average 99.3 ml (range 60-180 ml)
Study: 19830486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no contrast medium administered)
Study: 11095476
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide followed by 50 mg captopril after 7 days of EE
Study: 8810655
Drug: Desmin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 100 mg once daily SC
Study: 8810655
Drug: Desmin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 100 mg twice a day SC
Study: 8810655
Drug: Desmin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 200 mg once daily IM
Study: 8810655
Drug: Desmin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin (all doses)
Study: 1350796
Drug: lisinopril (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (10‐20 mg once daily)
Study: 1350796
Drug: hydrochlorothiazide (12.5‐25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (12.5‐25 mg once daily)
Study: 1350796
Drug: beta-blocker +
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker + ACE inhibitor
Study: 4083464
Drug: Nimodipine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 1.0 micrograms/kg body weight per minute in addition to 0.1 mg fentanyl/patient
Study: 4083464
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl anaesthesia (mean: 2.45 mg fentanyl/patient)
Study: 31221297
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) supplementation (35 g daily)
Study: 28202846
Drug: MFGM tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM tablets (1 g MFGM/d)
Study: 24670140
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Study: 24670140
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Study: 24670140
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1) with 0.4 g.kg‐1.h‐1 whey protein hydrolysate
Study: 22812907
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration 35-36 h prior to oocyte retrieval (Group A)
Study: 22812907
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration delayed by 1 day (Group B)
Study: 22812907
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration delayed by 2 days (Group C)
Study: 20116841
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ulipristal acetate
Study: 20116841
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg levonorgestrel
Study: 12919339
Drug: Eight drugs
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight drugs for primary generalized tonic-clonic seizures
Study: 1462990
Drug: ALG 15
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG 15 mg/kg just before transplant surgery, ALG 12 mg/kg the first day after transplant, followed by four doses of 10 mg/kg on alternate days
Study: 1462990
Drug: OKT3 5
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 5 mg just before transplant, followed by four doses of 5 mg/d
Study: 4028871
Drug: Lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg
Study: 26091383
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg
Study: 28535959
Drug: 1ml/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/kg of 0.25% caudal‐bupivacaine and 1mg/kg rectal‐diclofenac
Study: 28535959
Drug: 1ml/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/kg of 0.25% caudal‐bupivacaine and 30mg/kg rectal paracetamol
Study: 21659058
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium (6x419 mg Mg chloride/capsule per day for a month)
Study: 16555167
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract STW3-VI (900 mg)
Study: 16279863
Drug: Olanzapine combined
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine combined with fluoxetine
Study: 16279863
Drug: Risperidone added
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone added to ongoing therapy
Study: 10996349
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (1 or 2 tablets per day)
Study: 10996349
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (1 tablet per day)